Major Journal under Fire for Omitting Pfizer’s Failed Flu Data in Seniors (opens in new tab)

by at This week, I reported that Pfizer’s mRNA flu shot offered almost no clinical benefit in adults aged 18–64 — and that the harms were more significant than the headlines suggested. But that was not the full story. The New England Journal of Medicine (NEJM) did not publish any data from the older adults in the same trial — the very population most at risk from influenza and the main reason these vaccines exist. Instead, the over-65 results were quietly uploaded to ClinicalTrials.gov, where...